<DOC>
	<DOCNO>NCT01586338</DOCNO>
	<brief_summary>Primary Objective : - To evaluate change Western Ontario McMaster Universities Osteoarthritis Index ( WOMAC ) A1 subscore ( walk pain ) 26 week compare Baseline score - To evaluate safety use incidence , severity , seriousness , relatedness , frequency treatment emergent Adverse Events ( AEs ) Secondary Objectives : - To evaluate change WOMAC A1 subscore ( walk pain ) baseline week 8 , 12 - To evaluate change WOMAC A , B C score baseline week 8 , 12 26 - To evaluate change Patient Global Assessment ( PTGA ) score baseline week 8 , 12 26 - To evaluate change Clinical Observer Global Assessment ( COGA ) score baseline week 8 , 12 26 - To evaluate change concomitant Osteoarthritis ( OA ) therapy 26 week baseline week 1 , 2 , 8 , 12 26</brief_summary>
	<brief_title>A Study Efficacy Safety Synvisc® Chinese Subjects With Symptomatic Osteoarthritis Knee ( )</brief_title>
	<detailed_description>Duration study period participant 26-28 week .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Hylan</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Inclusion criterion : 1 . The participant diagnosis OA Target Knee confirm recent XRay ( mild moderate joint space narrow and/or osteophyte predominant tibiofemoral compartment ) 2 . WOMAC A1 baseline 100 mm Visual Analog Score ( VAS ) 4080 mm ( moderate severe walk pain ) Target knee 3 . Participants bilateral disease include study strict condition : Only one knee include efficacy assessment consider Target Knee ( The bad knee WOMAC A1 pain scale select ) . The selected knee must meet inclusion exclusion criteria The nontarget knee might also treat Synvisc® need meet KellgrenLawrence ( KL ) grade knee specific inclusion criterion describe . The criterion apply , include safety assessment 4 . Premenopausal female participant negative urine pregnancy test continue use medically acceptable form contraception duration study . Otherwise , females surgically sterile , postmenopausal ( documented medical history ) least 1 year Exclusion criterion : 1 . Significant ( require surgical correction ) valgus varus deformity knee , ligamentous laxity , meniscal instability 2 . Concomitant inflammatory disease/condition might affect joint ( e.g. , rheumatoid arthritis , metabolic bone disease , psoriasis , gout , pseudogout , chondrocalcinosis etc ) 3 . History sepsis joint clinical concern subacute infectious process target joint 4 . History surgery target knee ( do &lt; 6 month ) 5 . Planned surgery lower extremity joint 6 . Presence clinically significant venous lymphatic stasis leg ( ) 7 . Clinically apparent tense effusion inflammation target knee 8 . Skin disease infection area injection site 9 . Any musculoskeletal condition would impede measurement efficacy target knee 10 . Pregnant lactate woman 11 . Hypersensitivities avian protein and/or component hyaluronanbased injection 12 . Treatment Hyaluronic Acid ( HA ) derivatives previous 6 month . 13 . Treatment IntraArticular ( IA ) steroid previous 3 month 14 . Any contraindication IA injection e.g. , anticoagulant therapy clinical concern potential coagulopathy ( e.g . liver disease ) 15 . Any significant medical condition ( e.g. , significant psychiatric neurological disorder , active alcohol/drug abuse , etc ) , medical condition unstable/poorly control factor ( e.g. , plan relocation ) Investigator felt would interfere study evaluation study participation The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>